Cargando…
Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase
The inclusion of asparaginase in chemotherapy regimens to treat acute lymphoblastic leukemia (ALL) has had a positive impact on survival in pediatric patients. Historically, asparaginase has been excluded from most treatment protocols for adolescent and young adult (AYA) patients because of perceive...
Autores principales: | Boissel, Nicolas, Sender, Leonard S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575545/ https://www.ncbi.nlm.nih.gov/pubmed/26421220 http://dx.doi.org/10.1089/jayao.2015.0014 |
Ejemplares similares
-
Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia
por: Underwood, Brynne, et al.
Publicado: (2020) -
Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment
por: Rizzari, Carmelo, et al.
Publicado: (2014) -
Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019) -
L-Asparaginase Toxicity in the Treatment of Children and Adolescents with Acute Lymphoblastic Leukemia
por: Schmidt, Madalina-Petronela, et al.
Publicado: (2021) -
Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022)